High Times
Home > Boards > US OTC > Medical - Equipment > Arrayit Corporation (ARYC)

Arrayit Corporation Achieves Testing Accuracy Required for Medicare

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
techmover Member Profile
Member Level 
Followed By 87
Posts 12,268
Boards Moderated 1
Alias Born 04/13/10
160x600 placeholder
Arrayit Corporation Aces Three Consecutive Rounds of Proficiency Testing with the College of American Pathologists GlobeNewswire Inc. - 10/8/2018 5:30:00 AM
Arrayit Corporation Ships Clinical Instrumentation and Software to the United States Food and Drug Administration GlobeNewswire Inc. - 9/24/2018 5:30:00 AM
Arrayit Corporation Approved for Direct Medicare Billing by the Centers for Medicare and Medicaid Services GlobeNewswire Inc. - 9/10/2018 5:30:00 AM
Arrayit Corporation Announces Allergy Testing Partnerships with Major Allergy Therapeutics Providers GlobeNewswire Inc. - 8/27/2018 5:30:00 AM
Arrayit Corporation Receives Approval for In-Store Promotions by a Major Retail Chain GlobeNewswire Inc. - 8/13/2018 5:30:00 AM
Arrayit Corporation Signs Allergy Testing Contracts with a Nationwide Consortium of Medical Clinics GlobeNewswire Inc. - 7/30/2018 5:30:00 AM
Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration GlobeNewswire Inc. - 7/16/2018 5:30:00 AM
Arrayit Corporation Completes Allergy Testing Pilot Program for One of the Nation’s Largest Retail Chains GlobeNewswire Inc. - 7/2/2018 5:30:00 AM
Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network GlobeNewswire Inc. - 6/18/2018 5:30:00 AM
Arrayit Corporation Achieves Testing Accuracy Required for Medicare and Medicaid Reimbursement GlobeNewswire Inc. - 5/30/2018 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/9/2018 1:55:34 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 3/22/2018 2:12:50 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/19/2018 6:37:10 PM
techmover Member Level  Wednesday, 05/30/18 08:49:16 AM
Re: None
Post # of 104067 

Arrayit Corporation Achieves Testing Accuracy Required for Medicare and Medicaid Reimbursement
Print
Alert
Sunnyvale, CA , May 30, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company has achieved the clinical testing accuracy required for reimbursement under Medicare and Medicaid. Accuracy testing, supervised by the College of American Pathologists (CAP), assesses quantitative measurements of the immunoglobulin E (IgE) regulated analyte in the general immunology proficiency testing program. Arrayit’s testing performance included a score of 100% on the SA-2018 proficiency event and constituted successful cumulative performance required by the Centers for Medicare and Medicaid Services (CMS) over a one-year testing period. CMS regulates approximately 260,000 clinical laboratories through the Clinical Laboratory Improvement Amendments (CLIA) program, and proper certification is required to receive Medicare and Medicaid payments.

Arrayit is pioneering next generation personalized medicine tests that utilize non-invasive finger stick blood sampling, convenient blood card collection and patented and proprietary microarray technology to accurately and rapidly test analytes in the bloodstream that can assist in identifying and treating allergy, asthma and food intolerance. These tests are being offered through major brands to hospitals, health maintenance organizations (HMOs), clinical laboratories, physician groups, consumers through the assistance of medical doctors, and patients covered by the Medicare and Medicare federal health insurance programs. Medicare and Medicaid services combine for more than $1,200,000,000,000 ($1.2 trillion) in total healthcare expenditures annually for the 117 million recipients.

Arrayit CEO Rene Schena states, “Achieving the accuracy benchmark required for Medicare and Medicaid reimbursement allows us to expand the availability of our personalized medicine products to assist healthcare providers covering a large number of American families with government insurance. The non-invasiveness of our finger stick blood tests is particularly suited for young people, seniors and demographics requiring monitoring at regular intervals for allergy, asthma, food intolerance and other lifestyle indications.”


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist